These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 25457180)

  • 41. Conformationally constrained potent inhibitors for enhancer of zeste homolog 2 (EZH2).
    Xu X; Chen J; Wang G; Zhang X; Li Q; Zhou X; Guo F; Li M
    Bioorg Med Chem Lett; 2024 Jan; 97():129558. PubMed ID: 37956762
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reaction coupling between wild-type and disease-associated mutant EZH2.
    Swalm BM; Knutson SK; Warholic NM; Jin L; Kuntz KW; Keilhack H; Smith JJ; Pollock RM; Moyer MP; Scott MP; Copeland RA; Wigle TJ
    ACS Chem Biol; 2014 Nov; 9(11):2459-64. PubMed ID: 25154026
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Novel 3-methylindoline inhibitors of EZH2: Design, synthesis and SAR.
    Ansari A; Satalkar S; Patil V; Shete AS; Kaur S; Gupta A; Singh S; Raja M; Severance DL; Bernales S; Chakravarty S; Hung DT; Pham SM; Herrera FJ; Rai R
    Bioorg Med Chem Lett; 2017 Jan; 27(2):217-222. PubMed ID: 27923618
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis.
    Caganova M; Carrisi C; Varano G; Mainoldi F; Zanardi F; Germain PL; George L; Alberghini F; Ferrarini L; Talukder AK; Ponzoni M; Testa G; Nojima T; Doglioni C; Kitamura D; Toellner KM; Su IH; Casola S
    J Clin Invest; 2013 Dec; 123(12):5009-22. PubMed ID: 24200695
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Development and implementation of a high-throughput AlphaLISA assay for identifying inhibitors of EZH2 methyltransferase.
    Simard JR; Plant M; Emkey R; Yu V
    Assay Drug Dev Technol; 2013 Apr; 11(3):152-62. PubMed ID: 23409774
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Structure of the catalytic domain of EZH2 reveals conformational plasticity in cofactor and substrate binding sites and explains oncogenic mutations.
    Wu H; Zeng H; Dong A; Li F; He H; Senisterra G; Seitova A; Duan S; Brown PJ; Vedadi M; Arrowsmith CH; Schapira M
    PLoS One; 2013; 8(12):e83737. PubMed ID: 24367611
    [TBL] [Abstract][Full Text] [Related]  

  • 47. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation.
    Béguelin W; Popovic R; Teater M; Jiang Y; Bunting KL; Rosen M; Shen H; Yang SN; Wang L; Ezponda T; Martinez-Garcia E; Zhang H; Zheng Y; Verma SK; McCabe MT; Ott HM; Van Aller GS; Kruger RG; Liu Y; McHugh CF; Scott DW; Chung YR; Kelleher N; Shaknovich R; Creasy CL; Gascoyne RD; Wong KK; Cerchietti L; Levine RL; Abdel-Wahab O; Licht JD; Elemento O; Melnick AM
    Cancer Cell; 2013 May; 23(5):677-92. PubMed ID: 23680150
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Overexpression of enhancer of zests homolog 2 in lymphoma.
    Guo SQ; Zhang YZ
    Chin Med J (Engl); 2012 Oct; 125(20):3735-9. PubMed ID: 23075734
    [TBL] [Abstract][Full Text] [Related]  

  • 49. EZH2-mediated inactivation of IFN-γ-JAK-STAT1 signaling is an effective therapeutic target in MYC-driven prostate cancer.
    Wee ZN; Li Z; Lee PL; Lee ST; Lim YP; Yu Q
    Cell Rep; 2014 Jul; 8(1):204-16. PubMed ID: 24953652
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Allosteric Inactivation of Polycomb Repressive Complex 2 (PRC2) by Inhibiting Its Adapter Protein: Embryonic Ectodomain Development (EED).
    Yang CY; Wang S
    J Med Chem; 2017 Mar; 60(6):2212-2214. PubMed ID: 28256832
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Diverse, Potent, and Efficacious Inhibitors That Target the EED Subunit of the Polycomb Repressive Complex 2 Methyltransferase.
    Bagal SK; Gregson C; O' Donovan DH; Pike KG; Bloecher A; Barton P; Borodovsky A; Code E; Fillery SM; Hsu JH; Kawatkar SP; Li C; Longmire D; Nai Y; Nash SC; Pike A; Robinson J; Read JA; Rawlins PB; Shen M; Tang J; Wang P; Woods H; Williamson B
    J Med Chem; 2021 Dec; 64(23):17146-17183. PubMed ID: 34807608
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Non-Hodgkin's lymphoma: the old and the new.
    Cabanillas F
    Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S87-90. PubMed ID: 22035756
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance.
    Brooun A; Gajiwala KS; Deng YL; Liu W; Bolaños B; Bingham P; He YA; Diehl W; Grable N; Kung PP; Sutton S; Maegley KA; Yu X; Stewart AE
    Nat Commun; 2016 Apr; 7():11384. PubMed ID: 27122193
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Development and validation of reagents and assays for EZH2 peptide and nucleosome high-throughput screens.
    Diaz E; Machutta CA; Chen S; Jiang Y; Nixon C; Hofmann G; Key D; Sweitzer S; Patel M; Wu Z; Creasy CL; Kruger RG; LaFrance L; Verma SK; Pappalardi MB; Le B; Van Aller GS; McCabe MT; Tummino PJ; Pope AJ; Thrall SH; Schwartz B; Brandt M
    J Biomol Screen; 2012 Dec; 17(10):1279-92. PubMed ID: 22904200
    [TBL] [Abstract][Full Text] [Related]  

  • 55. De novo peptide design and experimental validation of histone methyltransferase inhibitors.
    Smadbeck J; Peterson MB; Zee BM; Garapaty S; Mago A; Lee C; Giannis A; Trojer P; Garcia BA; Floudas CA
    PLoS One; 2014; 9(2):e90095. PubMed ID: 24587223
    [TBL] [Abstract][Full Text] [Related]  

  • 56. EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL.
    Brach D; Johnston-Blackwell D; Drew A; Lingaraj T; Motwani V; Warholic NM; Feldman I; Plescia C; Smith JJ; Copeland RA; Keilhack H; Chan-Penebre E; Knutson SK; Ribich SA; Raimondi A; Thomenius MJ
    Mol Cancer Ther; 2017 Nov; 16(11):2586-2597. PubMed ID: 28835384
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhibition of the deubiquitinating enzyme USP47 as a novel targeted therapy for hematologic malignancies expressing mutant EZH2.
    Yang J; Weisberg EL; Qi S; Ni W; Mei H; Wang Z; Meng C; Zhang S; Hou M; Qi Z; Wang A; Jiang Y; Jiang Z; Huang T; Liu Q; Magin RS; Doherty L; Wang W; Liu J; Buhrlage SJ; Liu Q; Griffin JD
    Leukemia; 2022 Apr; 36(4):1048-1057. PubMed ID: 35034955
    [TBL] [Abstract][Full Text] [Related]  

  • 58. USP21 promotes cell proliferation by maintaining the EZH2 level in diffuse large B-cell lymphoma.
    Ma H; Luo X; Zhou P; He N; Zhou J; Liu M; Xie W
    J Clin Lab Anal; 2021 Mar; 35(3):e23693. PubMed ID: 33389794
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Degradation of Polycomb Repressive Complex 2 with an EED-Targeted Bivalent Chemical Degrader.
    Potjewyd F; Turner AW; Beri J; Rectenwald JM; Norris-Drouin JL; Cholensky SH; Margolis DM; Pearce KH; Herring LE; James LI
    Cell Chem Biol; 2020 Jan; 27(1):47-56.e15. PubMed ID: 31831267
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rapid Identification of Novel Allosteric PRC2 Inhibitors.
    Read JA; Tart J; Rawlins PB; Gregson C; Jones K; Gao N; Zhu X; Tomlinson R; Code E; Cheung T; Chen H; Kawatkar SP; Bloecher A; Bagal S; O'Donovan DH; Robinson J
    ACS Chem Biol; 2019 Oct; 14(10):2134-2140. PubMed ID: 31525019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.